VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Up 22.2% in June

VYNE Therapeutics Inc. (NASDAQ:VYNE) saw a large increase in short interest in the month of June. As of June 15th, there was short interest totalling 62,700 shares, an increase of 22.2% from the May 31st total of 51,300 shares. Based on an average daily trading volume, of 92,100 shares, the short-interest ratio is currently 0.7 days. Currently, 0.5% of the company’s shares are sold short.

VYNE Therapeutics Stock Down 2.5 %

Shares of NASDAQ VYNE opened at $1.92 on Tuesday. The business has a fifty day simple moving average of $2.42 and a two-hundred day simple moving average of $2.35. The firm has a market cap of $27.90 million, a PE ratio of -0.35 and a beta of 1.33. VYNE Therapeutics has a twelve month low of $1.57 and a twelve month high of $6.79.

VYNE Therapeutics (NASDAQ:VYNE) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.09. The company had revenue of $0.10 million during the quarter, compared to the consensus estimate of $0.10 million. VYNE Therapeutics had a negative net margin of 6,874.47% and a negative return on equity of 56.75%. On average, research analysts expect that VYNE Therapeutics will post -0.77 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $5.75 target price on shares of VYNE Therapeutics in a research report on Friday, June 14th.

Institutional Trading of VYNE Therapeutics

Several hedge funds have recently modified their holdings of VYNE. Virtu Financial LLC purchased a new position in VYNE Therapeutics in the first quarter worth $50,000. Parkman Healthcare Partners LLC acquired a new stake in shares of VYNE Therapeutics during the fourth quarter worth $1,623,000. Finally, Eventide Asset Management LLC purchased a new stake in shares of VYNE Therapeutics during the fourth quarter valued at $3,249,000. 83.78% of the stock is owned by hedge funds and other institutional investors.

About VYNE Therapeutics

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.